Our commitment to improving the lives of people living with serious medical conditions
For the past two decades, Collegium Pharmaceutical has been focused on developing and commercializing new medicines for pain management. Today, our mission is to build a leading, diversified specialty pharmaceutical company that reflects our Core Values and our commitment to improving the lives of people living with serious medical conditions. Through internal product development and the acquisitions of the Nucynta franchise in 2020 and BioDelivery Sciences International (BDSI) in 2022, we have broadened our portfolio of products to include meaningfully differentiated medications.
OUR PAIN MANAGEMENT PORTFOLIO
Acute and chronic pain impacts millions of Americans every year
There are two broad categories of pain based on duration: acute pain, or pain that is self-limited and generally requires treatment for no more than up to a few weeks, and chronic pain, or pain that lasts beyond the healing of an injury or that persists longer than three to six months. Approximately 40 million adults in the U.S. are affected by chronic pain each year, and at least 14 million of those adults experience high-impact chronic pain that interferes with daily life or work activities most days or every day. Prescription opioids continue to serve as important tools in the treatment of acute and chronic pain where alternative treatments have been inadequate.
Statistics for pain and pain management in the United States
U.S. adults annually experience chronic pain
of those with chronic pain experience high-impact pain
$560 billion +
in healthcare and productivity costs each year linked to chronic pain
Addressing the Opioid Epidemic
The misuse, abuse, and diversion of prescription opioids have contributed to today’s opioid crisis. In 2018, it was estimated that 9.2 million adults misused prescription analgesics. Striking the right balance between providing access for legitimate and well-supervised patients to innovative and effective therapies and protecting our communities from the significant risks associated with opioid misuse, abuse, and diversion is a critical part of our core values at Collegium. We believe that, until innovation obviates the need for opioid therapies, differentiated products and responsible engagement by pharmaceutical companies can play an important role in addressing our nation’s opioid abuse epidemic.
Today, we have a portfolio of innovative and differentiated pain medicines, supported by a team of professionals dedicated to fostering responsible pain management. We recognize that it is about more than medicine: it is about people living with pain, providers, communities, and the entire ecosystem in which we operate.
OUR NEUROLOGY PORTFOLIO
Migraines are one of the world’s most prevalent illnesses, and it is estimated that about 25% of families have someone living with migraine pain.1
There are four potential stages of a migraine: prodrome, aura, attack, and postdrome. Prodrome is the onset of the migraine. The aura stage is the second warning sign of a potential migraine in which migraine sufferers experience disturbances in their senses, like blurry vision or numbness. The attack stage is the headache phase and includes head pain that ranges from mild to debilitating. The postdrome stage is recovery from migraine.
Migraine affects almost 40 million people in the U.S.1, 2 and patients seek treatments that provide rapid and lasting relief from the symptoms. Our portfolio now includes a product that provides therapeutic options for people living with migraines.